Nose-to-Brain Delivery of Biopharmaceuticals via Non-covalent Strategy with Cell-Penetrating Peptides
Project/Area Number |
25860031
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Physical pharmacy
|
Research Institution | Kobe Gakuin University |
Principal Investigator |
|
Research Collaborator |
TAKEDA Mariko (MORISHITA Mariko)
WATANABE Yasuyoshi
KANAYAMA Yousuke
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 脳内デリバリー / 経鼻投与 / バイオ薬物 / 細胞膜透過ペプチド / インスリン / インクレチン / 脳デリバリー / バイオ医薬品 / アルツハイマー型認知症 / 非侵襲的デリバリー / アルツハイマー病 |
Outline of Final Research Achievements |
The biopharmaceuticals are required to permeate through blood-brain barrier (BBB) for achieving the efficient therapeutic effect in central nervous system (CNS). In this study, we therefore tried to develop the successful strategy for brain delivery of biopharmaceuticals via the direct nose-to-brain transport, which can bypass the BBB. The biopharmaceuticals coadministered intranasally with cell-penetrating peptides (CPPs) was efficiently delivered to the brain parenchyma including cerebral cortex and hippocampus, and eventually showed the therapeutic actions for CNS disorders. This study opened new avenues for developing a novel CNS pharmacotherapy with biopharmaceuticals.
|
Report
(4 results)
Research Products
(20 results)